Next Generation Complement Therapeutics Market Report 2025

The next generation complement therapeutics market size has grown rapidly in recent years. It will grow from $6.36 billion in 2024 to $7.38 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to the rising adoption of companion diagnostics, the increasing shift toward personalized treatment approaches, the expansion of telemedicine and digital health platforms, the growing focus on rare and orphan diseases, and the enhanced use of AI and machine learning in drug discovery.

The next generation of complement therapeutics market size is expected to see rapid growth in the next few years. It will grow to $13.24 billion in 2029 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to increasing investment from venture capital and private equity firms, the globalization of clinical trials, greater use of real-world evidence (RWE), rising diagnosis rates of neurodegenerative diseases, and the emergence of microbiome-based therapeutics. Key trends expected during this period include the integration of digital biomarkers in clinical trials, the adoption of CRISPR and gene-editing technologies, the development of multi-specific antibodies, the use of digital twins for patient simulation and precision care, and the application of 3D bioprinting for personalized drug testing and implants.

The increasing prevalence of chronic diseases is expected to drive growth in the next-generation complement therapeutics market in the coming years. Chronic diseases are long-term health conditions that require ongoing management to control symptoms and improve quality of life. Their rise is largely fueled by sedentary lifestyles that limit physical activity, disrupt metabolism, and increase long-term health risks. Next-generation complement therapeutics address chronic diseases by precisely targeting and modulating an overactive complement system to reduce inflammation and prevent tissue damage. For example, in January 2022, the American Cancer Society, a U.S.-based non-profit organization focused on cancer awareness, reported that approximately 1.9 million new cancer cases and 609,360 cancer-related deaths were expected in the U.S., translating to roughly 1,670 deaths per day. Consequently, the growing prevalence of chronic diseases is supporting the expansion of the next-generation complement therapeutics market.

Companies in the next-generation complement therapeutics market are developing advanced therapies, such as novel anti-C5 recycling monoclonal antibodies, to provide more effective treatments with less frequent administration for complement-mediated disorders. An anti-C5 recycling monoclonal antibody is a bioengineered molecule that targets and inhibits complement protein C5 to suppress inflammation while recycling in the body to prolong its half-life and therapeutic effect. For instance, in December 2022, Roche AG, a Switzerland-based pharmaceutical company, announced promising Phase III results from its COMMODORE 3 study, showing that crovalimab, a novel anti-C5 antibody, was effective and well-tolerated in patients with PNH in China. The therapy achieved its primary objectives of reducing blood transfusion requirements and controlling hemolysis. Designed for subcutaneous administration every four weeks, crovalimab offers a convenient, self-administered alternative to current treatments. With Priority Review granted by Chinese regulators, it may soon become a key treatment option for PNH, where access to C5 inhibitors is currently limited.

In May 2022, Vertex Pharmaceuticals, a U.S.-based pharmaceutical company, acquired Catalyst Biosciences’ complement portfolio for \$60 million. This acquisition expanded Vertex’s offerings in immune-related and rare diseases by providing access to advanced technologies targeting the C3 protein, a critical component of the immune system. Catalyst Biosciences, also based in the U.S., specializes in next-generation complement therapeutics.

Major players in the next generation complement therapeutics market are AstraZeneca PLC, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Vertex Pharmaceuticals, Genentech Inc., Genmab A/S, Mallinckrodt Pharmaceuticals Ltd., Alnylam Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Omeros Corporation, CANbridge Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Molecular Partners AG, NovelMed Therapeutics Inc., InflaRx GmbH, Amyndas Pharmaceuticals S.A., Kira Pharmaceuticals Inc., ReAlta Life Sciences Inc.

North America was the largest region in the next generation complement therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in next-generation complement therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the next-generation complement therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Next-generation complement therapeutics are advanced treatments developed to precisely regulate the complement system, a vital part of the immune response. These therapies leverage innovative strategies such as antibody-based treatments, RNA medicines, and gene editing to more effectively target complex immune and inflammatory disorders, while minimizing side effects compared to traditional approaches.

The primary types of next-generation complement therapeutics include monotherapy and adjunctive therapy. Monotherapy involves using a complement-targeted drug independently, without combining it with other treatments. These therapies consist of different molecule types, including biologics and small molecules, and are delivered through multiple routes of administration, such as intravenous, oral, intravitreal, and subcutaneous. They are designed to treat a wide range of indications, including paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA) associated with age-related macular degeneration, generalized myasthenia gravis, atypical hemolytic uremic syndrome (aHUS), and others. Their applications span various therapeutic areas, including hematology, ophthalmology, neurology, immunology, rheumatology, and beyond.

The next generation complement therapeutics market research report is one of a series of new reports that provides next generation complement therapeutics market statistics, including the next generation complement therapeutics industry global market size, regional shares, competitors with the next generation complement therapeutics market share, detailed next generation complement therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the next generation complement therapeutics industry. This next generation complement therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The next-generation complement therapeutics market consists of revenues earned by entities by providing services such as antibody engineering services, preclinical research services, biomanufacturing services, clinical trial management services, and regulatory consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation complement therapeutics market also includes sales of monoclonal antibodies, gene editing tools, small molecule inhibitors, recombinant proteins, and fusion proteins. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.